Format

Send to

Choose Destination

Links from PubChem BioAssay

See comment in PubMed Commons below
Eur J Med Chem. 2013 Aug;66:211-20. doi: 10.1016/j.ejmech.2013.05.022. Epub 2013 Jun 7.

Discovery of novel tetrahydro-pyrazolo [4,3-c] pyridines for the treatment of neuropathic pain: synthesis and neuropharmacology.

Author information

1
Neuropathic Pain Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science - Pilani, Hyderabad Campus, RR District, 500078 Andhra Pradesh, India. pyogee@hyderabad.bits-pilani.ac.in

Abstract

We disclose the discovery of a novel series of tetrahydropyrido-pyrazoles that are potent inhibitors of tumour necrosis factor-alpha (TNF-α), nitric oxide and cannabinoid receptor subtype 1 (CB₁). We report herein the synthesis and neuropharmacological screening results of the titled compounds in two acute pain and two neuropathic pain models in rodents. Particularly the analogue N-(4-bromophenyl)-3-tert-butyl-5-ethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-1-carboxamide (8a) exhibited pronounced acute antinociceptive efficacy, also being effective in chronic constriction injury (ED₅₀ = 23.8 mg/kg) and partial sciatic nerve injury (ED₅₀ = 29.0 mg/kg) models with CB₁ receptor activity (IC₅₀ = 49.6 nM) and inhibitory effect on TNF-α (86.4% inhibition at 100 mg/kg). These results suggest the importance of the development of this lead as multi-targeted treatment strategy for neuropathic pain.

KEYWORDS:

Antiallodynic; Antihyperalgesic; Antioxidant; Cannabinoid receptor; Nitric oxide; Tetrahydropyrazolo-pyridine

PMID:
23807113
DOI:
10.1016/j.ejmech.2013.05.022
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center